Abstract: A vascularized cardiac organoid with a chamber structure and its preparation method is presented. The cardiac organoids have a unique chamber structure, which includes a myocardium wall. Within the cardiac organoids, a vascular network is developed, enclosed within the myocardium wall. This vascular network is composed of endothelial cells surrounded by smooth muscle cells, forming a network of branched tubular structures. The presence of vasculature significantly promotes the arrangement of the myocardium, enhances the organization of the cardiac cytoskeleton, and promotes the consistency and beating frequency of cardiac cells. The vasculature facilitates the growth and size increase of the cardiac organoids.

Abstract: The present invention discloses a multi-channel impact-resistant intelligent-constant-deceleration hydraulic braking system, and relates to the field of safety braking control for mine hoist systems. A technical point of the braking system is that the braking system includes a braking circuit formed by a constant-deceleration hydraulic system, a constant-deceleration electrical closed-loop control system, and a detection and feedback apparatus. The constant-deceleration hydraulic system is provided with N+1 independent complete oil return channels, where N is a positive integer greater than or equal to 3. The oil return channels are disposed in parallel to form parallel independent braking circuits, that is, are “multi-channel” and do not have a “common output point”. The oil return channel includes a backup oil source, an electro-hydraulic signal conversion and amplification component, an operating mode switching apparatus, and an execution component that are sequentially connected.

Abstract: The techniques of the present disclosure provide a method of inhibiting tumor growth in a tissue of a mammal. The method includes administering to the mammal a therapeutically effective amount of a composition comprising an siRNA molecule that binds to an mRNA that codes for TGF?1 protein, an siRNA molecule that binds to an mRNA that codes for VEGFR2 protein, and a pharmaceutically acceptable carrier comprising a pharmaceutically acceptable polypeptide polymer. The techniques of the present disclosure also provide for additional methods for using this composition.

Abstract: Compositions and methods for development of potent siRNA therapeutics for prevention and treatment of Corona Virus (2019-nCoV; COVID-19) infections are provided. The compositions include a pharmaceutical composition comprising siRNA cocktails that target critical viral genes and pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers. Administration methods for prevention and treatment are provided, including airway instillation, subcutaneous injections and nebulizer aerosolization.